Pharma channel feed – Endpoints News

Pharma channel feed

Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug

7 years ago

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

7 years ago

#ESMO18: Cardio dreams blighted, Novartis showcases its “blockbuster” ambitions for radiopharmaceuticals

7 years ago

FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets

7 years ago

Amgen sharpens focus on genetic sequencing with $66M investment

7 years ago

AbbVie frontloads Morphic fibrosis development deal with $100M in cash

7 years ago

FDA slaps a full hold on Affimed's T cell engager in wake of a lethal reaction

7 years ago

Giant Pfizer looking to shed close to 2,000 jobs as it crafts a ‘simpler’ management structure

7 years ago

Allergan set to make headway in crowded CGRP migraine market, as the battle for formulary coverage begins

7 years ago

Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs

7 years ago

FDA lists 205 molecular targets for pediatric cancer research

7 years ago

Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins

7 years ago

Guest column: The real cost of drug development

7 years ago

ICER plots early scientific advice program for biopharma

7 years ago

AstraZeneca chairman repeats their position on investing in UK during Brexit talks, triggering fresh fears

7 years ago

Sanofi Genzyme has its expansive sights set on a new tech campus in Cambridge — report

7 years ago

SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer's lab

7 years ago

Experts offer a solid endorsement for AcelRx pain med, spurring a big rally for their stock

7 years ago

FDA sets record for number of generic drug approvals again

7 years ago

AbbVie staves off another US Humira knockoff to 2023 as European launch looms

7 years ago

Hit by FDA red flags, cited for misleading investors and battered by a thumbs-down from experts, it’s been one terrible week for Trevena

7 years ago

AcelRx rally quickly fizzles after FDA offers a guarded warning about its latest pain drug pitch

7 years ago

Trump signs bills to eliminate pharmacy ‘gag’ clauses

7 years ago

Teva-partnered Celltrion biosimilar scores FDA adcomm recommendation for a second shot at shaking up Roche's Rituxan franchise

7 years ago

First page Previous page 285 286 287288289 290 291 Next page Last page